The ACCORD study: The devil is in the details

David Siegel; Arthur L Swislocki

doi:10.1089/met.2010.0119

The ACCORD study: The devil is in the details

David Siegel, Arthur L Swislocki

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension, and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycosylated hemoglobin (HbA1c) levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a systolic blood pressure goal of 120mmHg did not significantly reduce major cardiovascular events. The authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD.

Original language	English (US)
Pages (from-to)	81-84
Number of pages	4
Journal	Metabolic Syndrome and Related Disorders
Volume	9
Issue number	2
DOIs	https://doi.org/10.1089/met.2010.0119
State	Published - Apr 1 2011

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Internal Medicine

Access to Document

10.1089/met.2010.0119

Fingerprint Dive into the research topics of 'The ACCORD study: The devil is in the details'. Together they form a unique fingerprint.

Cite this

@article{ae7d90c344124e54b4fc955f03bf0abd,

title = "The ACCORD study: The devil is in the details",

abstract = "The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension, and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycosylated hemoglobin (HbA1c) levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a systolic blood pressure goal of 120mmHg did not significantly reduce major cardiovascular events. The authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD.",

author = "David Siegel and Swislocki, {Arthur L}",

year = "2011",

month = apr,

day = "1",

doi = "10.1089/met.2010.0119",

language = "English (US)",

volume = "9",

pages = "81--84",

journal = "Metabolic Syndrome and Related Disorders",

issn = "1540-4196",

publisher = "Mary Ann Liebert Inc.",

number = "2",

}

TY - JOUR

T1 - The ACCORD study

T2 - The devil is in the details

AU - Siegel, David

AU - Swislocki, Arthur L

PY - 2011/4/1

Y1 - 2011/4/1

N2 - The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension, and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycosylated hemoglobin (HbA1c) levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a systolic blood pressure goal of 120mmHg did not significantly reduce major cardiovascular events. The authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD.

AB - The Action to Control Cardiovascular Risks in Diabetes Study (ACCORD) was a well-designed trial of 10,251 patients with type 2 diabetes mellitus that studied the effects of tight control of blood sugar, hypertension, and lipids. Disappointingly, as compared with standard treatment, the use of intensive therapy to target normal glycosylated hemoglobin (HbA1c) levels, tight lipid control by adding fenofibrate to a statin and aggressive blood pressure treatment with a systolic blood pressure goal of 120mmHg did not significantly reduce major cardiovascular events. The authors compare these results to other studies of the same issues and speculate about reasons for the lack of benefit in ACCORD.

UR - http://www.scopus.com/inward/record.url?scp=79953100939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953100939&partnerID=8YFLogxK

U2 - 10.1089/met.2010.0119

DO - 10.1089/met.2010.0119

M3 - Article

C2 - 21166575

AN - SCOPUS:79953100939

VL - 9

SP - 81

EP - 84

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 2

ER -